All Journals All Articles | Search Log In
Articles Special Topics Volumes Webinars Videos
Articles Special Topics Volumes Webinars Interviews

Volume

Emerging potential of CAR-NK cell therapy for hepatocellular carcinoma: current advances and translational challenges

Controlled attenuation parameter factors and steatosis grading in metabolic dysfunction-associated steatotic liver disease

Rewiring the tumor microenvironment in hepatocellular carcinoma: mechanism-driven integration of immunotherapy and locoregional strategies

Exploring the molecular pathology and tumor microenvironment in gastric cancer liver metastasis

Molecular characteristics of fatty acid metabolic reprogramming in hepatocellular carcinoma and their implications for immunotherapy

Converse therapeutic hierarchy in hepatocellular carcinoma

Application of <i>ex vivo</i> liver perfusion in hepatoma research

The evolving role of contrast-enhanced ultrasound in hepatocellular carcinoma: from diagnosis to therapeutic monitoring

Metabolic reprogramming and the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic targeting

Reconstructing strategies for precision diagnosis and treatment of liver cancer based on multi-modal data

The role of “treatment unfeasibility” in the multiparametric, multidisciplinary, and expert evaluation of HCC patients

Cordycepin alleviates oxaliplatin-induced fatty liver disease

Kupffer cells and monocyte-derived macrophages in the pathogenesis and treatment of hepatocellular carcinoma

Review of advances in FOLFOX-HAIC for conversion, neoadjuvant, and adjuvant therapy in hepatocellular carcinoma

Multi-task neural network enhanced by data augmentation and ROI optimization for prognosis and MVI prediction in HCC using contrast-enhanced CT

Histone lactylation in hepatocellular carcinoma: a key epigenetic hub linking metabolic reprogramming and the immune microenvironment

Resistance to immune checkpoint inhibitors in hepatocellular carcinoma: mechanisms and combination strategies to overcome it

Conversion and neoadjuvant systemic therapy for intrahepatic cholangiocarcinoma: from technical resectability to biology-driven surgical selection - a systematic review and meta-analysis

Patient-derived tumor organoid models for functional precision oncology in hepatocellular carcinoma

Yttrium-90 combination therapies in hepatocellular carcinoma: current evidence and future directions

Impact of metabolic reprogramming on the immune response in hepatocellular carcinoma

Incretin-based therapies: a new era in metabolic liver disease management

An activated CD8<sup>+</sup> T cell-based signature stratifies prognosis and suggests differential sensitivity to immune checkpoint inhibitors in hepatocellular carcinoma

<i>Helicobacter pylori</i> is associated with a higher risk of MAFLD prevalence and all-cause mortality: results from the NHANES III follow-up study

Targeting gut microbiota to overcome immunotherapy resistance in hepatocellular carcinoma: from mechanisms to clinical practice

Regional dietary patterns and risk of primary liver cancer in Anhui, China: a population-based case-control study

A systematic review of comparative economic analyses of systemic therapies for hepatocellular carcinoma

A review on decellularization scaffolding for liver regeneration in transplantation

Hepatocellular carcinoma tumor immune microenvironment: heterogeneity and therapeutic strategies

Gut microbiota as predictors of immunotherapy response in hepatocellular carcinoma

Global burden of liver cancer mortality due to alcohol use from 1990 to 2021 and predictions to 2050

Multidisciplinary management of HCC

From algorithm to dialogue: interpreting the 2026 BCLC-CUSE strategy for HCC care

Precision medicine in metabolic dysfunction-associated steatotic liver disease: genetics, epigenetics, and emerging therapies

Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual and triple agonists - mechanisms, clinical evidence, and therapeutic perspectives

Malnutrition in MASLD-related hepatocellular carcinoma: assessment limitations, multidimensional mechanisms, and microbiome-based interventions

Synergistic era: practice and reflection on TACE combined with systemic therapy in hepatocellular carcinoma

When a hazard ratio is not enough: non-proportional hazards are reshaping the interpretation of phase III trials in hepatocellular carcinoma

Rewiring neurotrophic signaling to escape targeted therapy in hepatocellular carcinoma

From platforms to pathways: imaging innovation, quantitative biomarkers, and clinical translation in hepatocellular carcinoma

Clinical applications and advances in noninvasive prognostic assessment of metabolic dysfunction-associated steatotic liver disease

Pseudocirrhosis: pathophysiology, clinical mimics, and its role in hepatocellular carcinoma diagnosis and management

Relationship between transarterial chemoembolization treatment frequency and prognosis in hepatocellular carcinoma patients

Fibroblast growth factor 21 in metabolic dysfunction-associated steatotic liver disease and beyond: from bench to bedside

Evolving epidemiology and antimicrobial resistance in cirrhosis: time for a region-specific approach

Pharmacological chemoprevention of hepatocellular carcinoma: hype, hope, or reality?

From gut-liver axis hijacking to intratumoral microbiota establishment: mechanisms and therapeutic opportunities in hepatocellular carcinoma

Beyond scarcity: rethinking transplant candidacy in the era of pig-to-human liver xenotransplantation

Advancing immunotherapy and tumor microenvironment research in hepatocellular carcinoma

Semaglutide and resmetirom for MASH: the AASLD Practice Guidance tells us when, not which

Is the second recurrence peak in HBV-related HCC fading in the antiviral era?

An immunocompetent model of hepacivirus-associated liver fibrosis and hepatocellular carcinoma

Metabolic memory and immune evasion in MASLD-HCC progression

Combining locoregional and systemic therapies in liver cancer: from strategy to survival

Is nicotinamide adenine dinucleotide the Achilles’ heel of chronic interleukin-6 signaling in cholangiocarcinoma?

Actions for 0 selected articles

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)
Navigation
Follow Us
Navigation

Committee on Publication Ethics

https://members.publicationethics.org/members/hepatoma-research

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://members.publicationethics.org/members/hepatoma-research

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/
Contact Us
Follow OAE
Twitter
Facebook
LinkedIn
YouTube
BiLiBiLi
WeChat
Rss
© 2016-2026 OAE Publishing Inc., except certain content provided by third parties